The FDA will fully approve Pfizer’s covid-19 vaccine next week

According to a report in the New York Times, the U.S. Food and drug administration may give full approval to Pfizer’s coronavirus vaccine as early as Monday. It is reported that regulators are trying to complete paperwork and negotiations with the company on Friday. Pfizer’s two doses of vaccine are currently being vaccinated in the United States under the emergency use authorization issued by FDA in December.
Pfizer and its partner biontech sought full approval from the U.S. Food and Drug Administration in May. Full approval will allow Pfizer to skip the procurement process and sell its vaccine directly to consumers, and may make it easier for government agencies and schools to obtain and vaccinate the public.
According to the Centers for Disease Control and prevention, the United States has received more than 203 million doses of Pfizer vaccine. Last week, the FDA and CDC signed a purchase agreement for the third dose of Pfizer and Moderna vaccine for some people with low immunity. On Wednesday, Biden Administration health officials said that fully immunized adults who have received Pfizer or Moderna vaccines will be eligible for intensive injections starting next month.
According to the New York Times, the FDA’s approval of Pfizer’s vaccine may be issued next Monday, which is expected to be much earlier than the agency’s expected completion date.
The food and Drug Administration declined to comment on the news.
Moderna is also seeking FDA approval for its covid-19 vaccine, but it is said that the approval decision may need to wait a few more weeks.